Arrowhead Pharmaceuticals (ARWR) Bank of America Global Healthcare Conference 2026 summary

Transition to commercial organization

• Transitioning from R&D to commercial focus while maintaining strong R&D momentum, now addressing seven cell types, five in clinical studies.

• Building a commercial force has been successful, with commercial and R&D efforts running in parallel.

• First data from the dimer (bispecific) platform expected in Q3, targeting mixed hyperlipidemia and CNS indications.

• Company remains at the forefront of RNAi innovation.

REDEMPLO launch and market strategy

• REDEMPLO launched for FCS, with over 400 prescriptions in the first full quarter, exceeding expectations.

• Focus on educating both patients and physicians, especially for clinical FCS and sHTG populations.

• Many high-risk sHTG patients may be misdiagnosed FCS cases; education is key to market expansion.

• Market development is a multi-step process: FCS, high-risk sHTG, then broader sHTG populations.

Competitive landscape and clinical differentiation

• sHTG market is large and benefits from two players, with both companies expected to grow the category.

• SHASTA-3 and SHASTA-4 pivotal data expected in Q3; focus on safety, triglyceride reduction, and pancreatitis outcomes.

• REDEMPLO showed no non-responders in FCS phase III, with expectations for strong and consistent efficacy.

• Potential clinical differentiation may include safety profile and absence of liver fat increase.